

# Daily Market Insights

## The Runaway Gaps

Monday, March 09, 2026



TradingView

### Market Brief

The index leaps above the 55 & 90-dema's forming a runaway gap between 10,885-10,846. This is the second gap since levels recover from a low of 10,193. The first gap was minor between 10,579-10,570 formed last Wednesday.

The decline from 11,484-10,193 has completed the 61.8% retracement at 10,991 and now faces the 200-dema as the key trailing resistance while extending above the key average, levels face 11,200. Immediate risk is defined below the recent gap that fills at 10,846. But not to be carried away, this recovery is still a hiccup within the downtrend from 12,536. Until a clear breakout sets in above the trend-line, a turnaround would not be classified.

### Outlook

Trend is Positive. Support levels come around 10,970 – 10,950. On the upside resistance levels come around 11,056 – 11,076.

### MARKET SUMMARY

Close	11,007.19
Intraday High/Low	11,021.99 / 10,885.55
Change (points)	230.87
Change (%)	2.14%
52 Week High/Low	12,075.11 / 10,193.83
1 Year Index Change (%)	-6.81%
Volume (mn)	282.9
Value (SR mn)	5,603.9

### INTRADAY INDEX LEVELS

Resistance 3	11,168
Resistance 2	11,107
Resistance 1	11,057
<b>Pivot</b>	<b>10,971</b>
Support 1	10,921
Support 2	10,871
Support 3	10,846

### INDICATORS

RSI (14 Days)	53.82
55-dema	10,926
90-dema	10,943
200-dema	11,076

### INTRADAY TRADING IDEAS

Name	Price	Rec.	Entry Range	TP1	TP2	SL	S1	S2	R1	R2	RSI	DAILY EMA's		
												21	55	90
ALRAJHI TAKAFUL	90.00	B	90.00-88.30	92.00	93.90	86.40	86.00	84.00	92.00	94.00	67.12	78.43	81.18	86.41
ALUJAIN	26.84	B	26.84-26.40	27.29	27.75	25.93	25.93	25.48	27.29	27.75	66.57	23.92	25.26	26.61
MARAFIQ	32.34	B	32.34-32.05	32.69	32.78	31.70	31.71	31.36	32.69	33.03	54.92	31.09	33.12	34.79

TP: Target Price, SL: Stop Loss

### TOP 10 VOLUME LEADERS

Name	Code	Last Price	Support 3	Support 2	Support 1	Pivot	Resistance 1	Resistance 2	Resistance 3
AMERICANA	6015	1.99	1.92	1.95	1.97	2.00	2.02	2.05	2.07
SAUDI ARAMCO	2222	26.94	26.17	26.41	26.67	26.91	27.17	27.41	27.67
CHEMICAL	2230	7.65	6.48	6.79	7.22	7.53	7.96	8.27	8.70
SAUDI KAYAN	2350	5.39	4.86	4.96	5.18	5.28	5.50	5.60	5.82
EIC	1303	16.20	14.72	15.35	15.78	16.41	16.84	17.47	17.90
BATIC	4110	2.00	1.88	1.92	1.96	2.00	2.04	2.08	2.12
JABAL OMAR	4250	15.05	14.30	14.55	14.80	15.05	15.30	15.55	15.80
SIECO	4140	2.29	2.19	2.22	2.26	2.29	2.33	2.36	2.40
APC	2200	5.00	4.44	4.57	4.78	4.91	5.12	5.25	5.46
SABIC	2010	59.70	54.48	55.57	57.63	58.72	60.78	61.87	63.93

# Stock of the Day SR 116.30

## DALLAH HEALTHCARE CO. (4004)



TradingView

### Stock Brief

Reaching a highly oversold state of momentum early this month with an RSI low at 18.11, the stock's recovery has been very spontaneous. Moves between Thursday and Wednesday last formed gap from 107.20-105.70. This gap is a continuation statement of this recovery.

Immediate resistance trails along the 55 & 90-dema's while the decline from 156.80 – 90.00 corrects levels of 50% and 61.8% at 123.40 and 131.30, respectively. The latter level coming just above the 200-dema. With risk below the gap at 105.70 upside is making headway towards 123.40 and likely test the 200-dema.

### Strategy

Buy from current levels and up to 113.70. Target 123.40 to sell. Stop on break below 105.70.

### STOCK SUMMARY

52 Week High/Low	157.30 - 90.00
1 Year Price Change (%)	-5.45%
Volume (000)	93
3M ADTV (SR 000)	13,770
Bloomberg	DALLAH AB
Reuters	4004.SE

### KEY PRICE LEVELS

Resistance 3	121.70
Resistance 2	120.00
Resistance 1	118.30
Support 1	115.50
Support 2	111.40
Support 3	107.20

### INDICATORS

RSI (14 Days)	58.19
55-dema	117.10
90-dema	121.70
200-dema	128.40

### Contact Details:

Research Department  
 research@anbcapital.com.sa  
 +966 11 4062500

## GLOSSARY OF TERMS

---

**Support:** Support is the level at which the stock is likely to see increased interest from buyers. The buying support will prevent the stock from falling further.

**Resistance:** Resistance is the level at which the stock is likely to see increased interest from sellers. The selling pressure will prevent the stock from rising further.

**RSI:** The Relative Strength Index (RSI) is a momentum oscillator that ranges from 0 to 100. It compares the extent of the stock's recent price movements by evaluating recent gains and losses. Stocks with RSI above 70 could be considered overbought, and below 30 could be considered oversold. Generally, if the RSI falls below 70, it is a bearish signal. Conversely, if the RSI of a stock rises above 30 it is considered bullish. The RSI used is of 14 days.

**Bollinger Bands:** A Bollinger Band, developed by famous technical trader John Bollinger, is plotted two standard deviations away from a simple moving average. BB is a highly popular technical analysis technique. Many traders believe the closer the prices move to the upper band, the more overbought the market, and the closer the prices move to the lower band, the more oversold the market.

**MACD:** MACD shows the relationship between a longer period moving average and a short period moving average of a stock's price. Generally, the 26-day exponential moving average (EMA) and the 12-day EMA are used to calculate MACD.

**EMA:** Exponential moving average (EMA) is the weighted average of the prices of a given security where higher weights are given to recent data points. EMA is used to analyze the trend of a stock.

## DISCLAIMER SECTION

---

### Analyst Certification of Independence

The analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report. The research analysts, strategists or research associates principally having received compensation responsible for the preparation of this research report based upon various factors including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

### Disclosure of Interest Area

The firm and the authoring analyst do not have any interest in any companies recommended in this research report irrespective of the fact that the firm may have, within the last three years, served as manager or co-manager of a public offering of securities for, or currently may make a primary market in issues of, any or all of the entities mentioned in this report or may be providing, or have provided within the previous 12 months, significant advice or investment services in relation to the investment concerned or a related investment.

### Regional Disclosures

The information provided in this report and the report itself is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject the firm or its affiliates to any registration or licensing requirements within such jurisdiction or country.

Furthermore, all copyrights, patents, intellectual and other property in the information contained in this report are held by the firm. No rights of any kind are licensed or assigned or shall otherwise pass to persons accessing this information. You may print copies of the report or information contained within herein for your own private non-commercial use only, provided that you do not change any copyright, trademark or other proprietary notices. All other copying, reproducing, trans-mitting, distributing or displaying of material in this report. (by any means and in whole or in part). The securities referred to in this Report may not be eligible for sale in some jurisdictions. This report is intended only for and, may be distributed only to, accredited investors, expert investors or institutional investors.

This report has been prepared by anb capital for information purposes only and is not and does not form part of nor should be considered advice, recommendation, offer for sale or solicitation of any offer to subscribe for, purchase or sell any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever, and any views or opinions expressed herein are subject to change without notice.

Under no circumstance will anb capital nor any of its respective directors, officers or employees be responsible or liable, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with the use of or reliance on the information contained in this report.